Market Buzz: CDI Trial Outcome Fuels Acurx Pharmaceuticals
- October 02nd, 2023
- 467 views
Shares of Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) surged by more than 20% in pre-market trading following the company's decision to discontinue its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, designed for the treatment of Clostridioides difficile infection (CDI).
The decision was due to the trial's success, with high clinical cure rates observed across the trial without any safety concerns for both ibezapolstat and the control antibiotic vancomycin.
This achievement has prompted the company to expedite its plans for Phase 3 clinical trials for this first-in-class antibiotic product candidate, which has earned FDA QIDP/Fast Track designation.
$ACXP was trading at $1.81 in pre-market, reflecting a remarkable increase of $0.38 (+26.57%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login